281 related articles for article (PubMed ID: 30393007)
1. Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders.
Pugh TJ; Fink JM; Lu X; Mathew S; Murata-Collins J; Willem P; Fang M;
Cancer Genet; 2018 Dec; 228-229():184-196. PubMed ID: 30393007
[TBL] [Abstract][Full Text] [Related]
2. Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms.
Kanagal-Shamanna R; Hodge JC; Tucker T; Shetty S; Yenamandra A; Dixon-McIver A; Bryke C; Huxley E; Lennon PA; Raca G; Xu X; Jeffries S; Quintero-Rivera F; Greipp PT; Slovak ML; Iqbal MA; Fang M
Cancer Genet; 2018 Dec; 228-229():197-217. PubMed ID: 30377088
[TBL] [Abstract][Full Text] [Related]
3. Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group.
Xu X; Bryke C; Sukhanova M; Huxley E; Dash DP; Dixon-Mciver A; Fang M; Griepp PT; Hodge JC; Iqbal A; Jeffries S; Kanagal-Shamanna R; Quintero-Rivera F; Shetty S; Slovak ML; Yenamandra A; Lennon PA; Raca G
Cancer Genet; 2018 Dec; 228-229():218-235. PubMed ID: 30344013
[TBL] [Abstract][Full Text] [Related]
4. Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia.
Chun K; Wenger GD; Chaubey A; Dash DP; Kanagal-Shamanna R; Kantarci S; Kolhe R; Van Dyke DL; Wang L; Wolff DJ; Miron PM
Cancer Genet; 2018 Dec; 228-229():236-250. PubMed ID: 30554732
[TBL] [Abstract][Full Text] [Related]
5. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
Mukherjee S; Sathanoori M; Ma Z; Andreatta M; Lennon PA; Wheeler SR; Prescott JL; Coldren C; Casey T; Rietz H; Fasig K; Woodford R; Hartley T; Spence D; Donnelan W; Berdeja J; Flinn I; Kozyr N; Bouzyk M; Correll M; Ho H; Kravtsov V; Tunnel D; Chandra P
Cancer Genet; 2017 Oct; 216-217():128-141. PubMed ID: 29025587
[TBL] [Abstract][Full Text] [Related]
6. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.
Ronaghy A; Yang RK; Khoury JD; Kanagal-Shamanna R
Curr Hematol Malig Rep; 2020 Jun; 15(3):194-202. PubMed ID: 32382988
[TBL] [Abstract][Full Text] [Related]
7. Implementation of cytogenomic microarray with plasma cell enrichment enables better abnormality detection and risk stratification in patients with plasma cell neoplasia than conventional cytogenetics and fluorescence in situ hybridization.
Chen C; Lim AST; Lau LC; Lim TH; Heng EYH; Tien SL
Cancer Genet; 2021 Apr; 252-253():25-36. PubMed ID: 33341677
[TBL] [Abstract][Full Text] [Related]
8. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, cross-platform clinical validation study of cancer cytogenomic arrays.
Li MM; Monzon FA; Biegel JA; Jobanputra V; Laffin JJ; Levy B; Leon A; Miron P; Rossi MR; Toruner G; Alvarez K; Doho G; Dougherty MJ; Hu X; Kash S; Streck D; Znoyko I; Hagenkord JM; Wolff DJ
Cancer Genet; 2015 Nov; 208(11):525-36. PubMed ID: 26454669
[TBL] [Abstract][Full Text] [Related]
10. Optical Genome Mapping as a Next-Generation Cytogenomic Tool for Detection of Structural and Copy Number Variations for Prenatal Genomic Analyses.
Sahajpal NS; Barseghyan H; Kolhe R; Hastie A; Chaubey A
Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33799648
[TBL] [Abstract][Full Text] [Related]
11. Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH.
Dong H; Yang HS; Jagannath S; Stephenson CF; Brenholz P; Mazumder A; Chari A
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):366-74. PubMed ID: 22658896
[TBL] [Abstract][Full Text] [Related]
12. Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia.
Akkari YMN; Bruyere H; Hagelstrom RT; Kanagal-Shamanna R; Liu J; Luo M; Mikhail FM; Pitel BA; Raca G; Shago M; Shao L; Smith LR; Smolarek TA; Yenamandra A; Baughn LB
Cancer Genet; 2020 May; 243():52-72. PubMed ID: 32302940
[TBL] [Abstract][Full Text] [Related]
13. Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay.
Chen C; Heng EYH; Lim AST; Lau LC; Lim TH; Wong GC; Tien SL
Int J Lab Hematol; 2019 Aug; 41(4):561-571. PubMed ID: 31112375
[TBL] [Abstract][Full Text] [Related]
14. Comparative Benchmarking of Optical Genome Mapping and Chromosomal Microarray Reveals High Technological Concordance in CNV Identification and Additional Structural Variant Refinement.
Barseghyan H; Pang AWC; Clifford B; Serrano MA; Chaubey A; Hastie AR
Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895217
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells.
Tang G; Wu Y; Lin P; Toruner GA; Hu S; Li S; Qazilbash MH; Orlowski RZ; Ye C; Xu J; Nahmod KA; Medeiros LJ; Tang Z
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067393
[TBL] [Abstract][Full Text] [Related]
16. A multimodal genomics approach to diagnostic evaluation of pediatric hematologic malignancies.
Hiemenz MC; Oberley MJ; Doan A; Aye L; Ji J; Schmidt RJ; Biegel JA; Bhojwani D; Raca G
Cancer Genet; 2021 Jun; 254-255():25-33. PubMed ID: 33571894
[TBL] [Abstract][Full Text] [Related]
17. Chromosomal defects in multiple myeloma.
Clarke SE; Fuller KA; Erber WN
Blood Rev; 2024 Mar; 64():101168. PubMed ID: 38212176
[TBL] [Abstract][Full Text] [Related]
18. Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia.
Tang Z; Kanagal-Shamanna R; Tang G; Patel K; Medeiros LJ; Toruner GA
Leuk Res; 2021 Sep; 108():106616. PubMed ID: 34022744
[TBL] [Abstract][Full Text] [Related]
19. FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia.
Dubuc AM; Davids MS; Pulluqi M; Pulluqi O; Hoang K; Hernandez-Sánchez JM; Schlich C; Hernández-Rivas JM; Brown JR; Dal Cin P
Am J Hematol; 2016 Oct; 91(10):978-83. PubMed ID: 27341486
[TBL] [Abstract][Full Text] [Related]
20. Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC).
Mikhail FM; Biegel JA; Cooley LD; Dubuc AM; Hirsch B; Horner VL; Newman S; Shao L; Wolff DJ; Raca G
Genet Med; 2019 Sep; 21(9):1903-1916. PubMed ID: 31138931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
